Mesenchymal stem cells from amniotic fluid for treating congenital and other diseases

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Over the past decade, amniotic fluid-derived mesenchymal stem/stromal cells (AF-MSCs) have emerged as a novel, experimental approach for the treatment of a wide variety of congenital anomalies diagnosed either in utero or postnatally. This article gives a pediatric surgeon’s perspective on AF-MSC therapy for the management of congenital anomalies and other diseases. The current status in preterm AF-MSC research, particularly as it relates to tissue engineering-based applications, is described in various experimental animal models. A roadmap for further study and eventual clinical application is also proposed.

Original languageEnglish (US)
Title of host publicationEncyclopedia of Tissue Engineering and Regenerative Medicine
PublisherElsevier
Pages513-520
Number of pages8
Volume1-3
ISBN (Electronic)9780128136997
ISBN (Print)9780128137000
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Keywords

  • Amniocytes
  • Amniotic fluid
  • Congenital anomalies
  • Fetal therapy
  • Fetus
  • Induced pluripotent stem cells
  • Mesenchymal stem cells
  • Stem cell therapy
  • Stem cells
  • Tissue engineering

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Mesenchymal stem cells from amniotic fluid for treating congenital and other diseases'. Together they form a unique fingerprint.

Cite this